{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:40:29Z","timestamp":1790624429754,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.blre.2022.101002","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:20:27Z","timestamp":1660713627000},"page":"101002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation"],"prefix":"10.1016","volume":"57","author":[{"given":"David","family":"Sermer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavania","family":"Elavalakanar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2022.101002_bb0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002371-199511000-00004","article-title":"Phase I trial of an anti-CD19 deglycosylated ricin a chain immunotoxin in non-Hodgkin\u2019s lymphoma: effect of an intensive schedule of administration","volume":"18","author":"Conry","year":"1995","journal-title":"J Immunother Emphasis Tumor Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0010","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V81.6.1549.1549","article-title":"Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study","volume":"81","author":"Pulczynski","year":"1993","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2022.101002_bb0015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2013.828354","article-title":"Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond","volume":"55","author":"Katz","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01741331","article-title":"Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody","volume":"32","author":"Hekman","year":"1991","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2022.101002_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.blre.2022.101002_bb0035","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"182","key":"10.1016\/j.blre.2022.101002_bb0040","article-title":"A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed\/refactory B-lineage non-hodgkin lymphoma","volume":"23","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2022.101002_bb0045","first-page":"459","article-title":"Phase I study of the CD19\/CD3 half-life extended BITE\u00ae molecule AMG 562 in relapsed\/refractory diffuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma","volume":"39","author":"Mead","year":"2021","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.101002_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0167-5699(94)90274-7","article-title":"The CD19\/CD21 signal transduction complex of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"issue":"10","key":"10.1016\/j.blre.2022.101002_bb0055","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.4049\/jimmunol.157.10.4371","article-title":"CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity","volume":"157","author":"Sato","year":"1996","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.blre.2022.101002_bb0060","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.158.10.4662","article-title":"CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19","volume":"158","author":"Sato","year":"1997","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2022.101002_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity."},{"issue":"7","key":"10.1016\/j.blre.2022.101002_bb0070","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.159.7.3278","article-title":"Regulation of B lymphocyte development and activation by the CD19\/CD21\/CD81\/Leu 13 complex requires the cytoplasmic domain of CD19","volume":"159","author":"Sato","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0075","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0080","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2022.101002_bb0085","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.blre.2022.101002_bb0090","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","article-title":"The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates","volume":"113","author":"Zalevsky","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2022.101002_bb0095","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2022.101002_bb0100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.101002_bb0105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicenter, prospective, single-arm phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.101002_bb0110","first-page":"1","article-title":"CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study","author":"Duell","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"Supp. 1","key":"10.1016\/j.blre.2022.101002_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood-2021-148302","article-title":"Tafasitamab plus lenalidomide versus pola BR, R2, and CAR T: comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed\/refractory diffuse large B-cell lymphoma","volume":"138","author":"Nowakowski","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2022.101002_bb0120","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0125","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood-2021-148354","article-title":"First-Mind: primary analysis from a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"138","author":"Belada","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2022.101002_bb0130","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2022.101002_bb0135","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.blre.2022.101002_bb0140","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood."},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0145","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2021-148730","article-title":"Clinical characteristics and responses of patients with relapsed or refractory high-grade B-cell lymphoma treated with loncastuximab tesirine in the Lotis-2 clinical trial","volume":"138","author":"Alderuccio","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.101002_bb0150","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2021-147765","article-title":"Planned interim analysis of a phase 2 study of loncastuximab tesirine plus Ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)","volume":"138","author":"Carlo-Stella","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2022.101002_bb0160","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2022.101002_bb0165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.20.01564","article-title":"Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2022.101002_bb0170","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2022.101002_bb0175","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.101002_bb0180","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0185","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2019-121708","article-title":"Open-label, phase 2 study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphoma","volume":"134","author":"Katz","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142464","article-title":"Blinatumomab consolidation post autologous hematopoietic stemcell transplantation in patients with diffuse large B cell lymphoma","volume":"136","author":"Ghobadi","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2022.101002_bb0195","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1800913","article-title":"CAR T-cell therapy in large B-cell lymphoma","volume":"378","author":"Neelapu","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2022.101002_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.blre.2022.101002_bb0205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.blre.2022.101002_bb0210","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.blre.2022.101002_bb0215","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2022.101002_bb0220","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.blre.2022.101002_bb0225","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DBLCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2022.101002_bb0230","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.blre.2022.101002_bb0235","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet."},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0240","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2021-148009","article-title":"Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0245","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1182\/blood-2019-128613","article-title":"Expression of CD19 antigen on chronic lymphocytic leukemia cells after tafasitamab (anti-CD19) treatment: phase I trial data","volume":"134","author":"Boxhammer","year":"2019","journal-title":"Blood"},{"issue":"3 Supplement","key":"10.1016\/j.blre.2022.101002_bb0250","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.bbmt.2019.12.201","article-title":"Targeting of CD19 By tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro","volume":"26","author":"Horvei","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0255","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2021-145649","article-title":"The impact of prior treatment with a CD19 targeting monoclonal antibody on subsequent treatment with CD19 targeting CART cell therapy in preclinical models","volume":"138","author":"Sakemura","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2022.101002_bb0260","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/10428194.2021.1992622","article-title":"CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas","volume":"63","author":"Fitzgerald","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2022.101002_bb0265","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The AntiCD19 antibody drug Immunoconjugate Loncastuximab achieves responses in DLBCL relapsing after AntiCD19 CAR-T cell therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2022.101002_bb0270","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2022.101002_bb0275","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2022.101002_bb0280","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0285","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2021-147433","article-title":"Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy","volume":"138","author":"Zurko","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0290","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2021-150994","article-title":"Outcome of relapsed\/refractory aggressive B-cell lymphoma patients relapsing after anti-CD19 CAR T-cells and enrolled in the Descar-T French national registry","volume":"138","author":"Di Blasi","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0295","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2021-147568","article-title":"Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: a multicenter observational study","volume":"138","author":"Tomas","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2022.101002_bb0300","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0305","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin's lymphoma: a phase I california cancer consortium study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.101002_bb0310","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1182\/blood-2021-147467","article-title":"Blinatumomab for patients with Richter\u2019s syndrome: a multicenter phase 2 trial from the filo group","volume":"138","author":"Guieze","year":"2021","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:33Z","timestamp":1759436913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":62,"alternative-id":["S0268960X22000765"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.101002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.101002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101002"}}